The combination of a mutant-selective EGFR-TKI and a Met inhibitor... | Download Scientific Diagram
MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib - Nishiyama - 2020 - Cancer Science - Wiley Online Library
![PDF] EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/fb34e0b378ab283ee885fb912c61cc28ae8a288b/3-Figure1-1.png "PDF] EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer | Semantic Scholar")
PDF] EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer | Semantic Scholar
PLOS ONE: MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer? - Cancer Treatment Reviews
1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC - ScienceDirect
MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregula | OTT
Reciprocal relationship between MET amplification and T790M mutation.... | Download Scientific Diagram
Frontiers | Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors | Oncology
EMT, MET amplification, and IGF-1R confer resistance to EGFR TKIs.... | Download Scientific Diagram
c-Met inhibitor - Wikipedia
MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer - Journal of Thoracic Oncology
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro - Journal of Thoracic Oncology
The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy - Lung Cancer
JCM | Free Full-Text | The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer | HTML
Met signaling pathway and EGF receptor tyrosine kinase inhibitor... | Download Scientific Diagram
Amivantamab: A Potent Novel EGFR/c-MET Bispecific Antibody Therapy for EGFR-mutated Non-small Cell Lung Cancer - touchONCOLOGY
EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression | Molecular Cancer | Full Text
Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench - Journal of Thoracic Oncology
MET amplification causes EGFR-TKI resistance by activating... | Download Scientific Diagram
AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation - Lung Cancer
PLOS ONE: MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
Molecular characterization and clinical outcomes in EGFR-mutant de novo MET-overexpressed advanced non-small-cell lung cancer - ESMO Open
